pyxisoncology.comCrawled Nov 2, 2026
Pyxis, a multiplatform company, is progressing an innovative biologics portfolio.
Pyxis Oncology researches antibody-drug conjugates and immunotherapies for difficult-to-treat cancers.
Pyxis Oncology develops antibody-drug conjugates and Immuno-Oncology treatments to improve outcomes for cancer patients.
Pyxis Oncology provides information about its company and work.
Charting a course to therapeutics for difficult-to-treat cancers.
Pyxis Oncology reports **MICVO** achieves a **36% confirmed objective response rate** and **94% disease control rate** in Phase 1 trials. Clinical activity is observed across **HPV-positive and HPV-negative subgroups**, as well as patients with prior treatments. The updated data highlights the drug’s potential efficacy in diverse patient populations.
Sep 2026Pyxis OncologyNews article
Pyxis Oncology highlights preclinical data for micvotabart pelidotin (MICVO), demonstrating its three-pronged anti-tumor mechanism. The therapy targets tumors through direct cell killing, a bystander effect, and immunogenic cell death. These findings support its potential as a novel cancer treatment candidate.
May 2025BioSpaceNews article
Pyxis Oncology secures **$168 million** from its IPO to accelerate research using **antibody drug conjugate (ADC) technology** licensed from Pfizer. The funding follows a surge in ADC approvals, with **six new FDA-approved drugs** entering the market in the past two years. The company joins a wave of life science firms raising nearly **$500 million** in Q4 to develop next-generation cancer therapies.
Oct 2021MedCity NewsNews article
Pyxis Oncology secures $22 million in Series A funding to develop antibody-based immunotherapies targeting the tumor microenvironment. The company leverages novel biological insights to create a new class of immuno-oncology treatments. Bayer leads the financing, with additional contributions from institutional and strategic investors.
Jul 2019Agent CapitalNews article
